๐ Pharmidex Announcement: Celebrating Dr. Christopher Ireson’s New Role ๐
January 28, 2025
We are excited and proud to share that our Head of Oncology, Dr. Christopher Ireson, has been named as a member of the Translational Advisory Board of the Brain Tumour Charity! ๐ง ๐ผ
๏ปฟ
Dr. Ireson’s extensive expertise in oncology will help drive impactful scientific advancements and translational research to improve outcomes for brain tumour patients. We are incredibly grateful to have such a talented leader in our team contributing to this important cause. ๐
Please join us in congratulating Dr. Ireson on this achievement! ๐
#Pharmidex #Oncology #TranslationalResearch #BrainTumourCharity #ProudMoment #ScientificAdvisoryBoard
Pharmidex team are delighted to participate in workshop on "Re-shaping UK life science commercialisation strategy" organised by The Research and Development Society on Wednesday 11th June, at Mereside, Alderley Park. If you are attending, please linkup with our colleague Mo Alavijeh who will be delighted to meet you. Jamie Phadke , Alderley Park #UKlifescience https://lnkd.in/e6uKsRcN
Martin Barrett , Head of Business Development, will attend the symposium on 10–13 June 2025 at Hotel Comwell Borupgaard, Denmark. The event gathers top European scientists to discuss drug discovery. Martin looks forward to connecting with academia, CROs, and pharma to explore collaborations and showcase Pharmidex’s services from in silico to in vivo pharmacology. Attending? Let’s connect! ๐ https://lnkd.in/ev7TW7WG
We’re excited to announce our involvement in the recent publication: "Anti-Inflammatory Activity of Ensifentrine: A Novel, Selective Dual Inhibitor of PDE3 and PDE4" ๐ https://pubmed.ncbi.nlm.nih.gov/40245851/ ๐ https://www.pharmidex.com/publications-by-pharmidex Dr. Radhakrishnan Venkatasamy , our Senior Scientist in autoinflammatory and immune diseases, co-authored this study highlighting Ensifentrine’s anti-inflammatory potential. This reflects Pharmidex’s commitment to advancing therapies through expert science and collaboration.
